| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes ME MacDonald, CM Ambrose, MP Duyao, RH Myers, C Lin, L Srinidhi, ... Cell 72 (6), 971-983, 1993 | 7689 | 1993 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1850 | 2018 |
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry KY Chung, J Shia, NE Kemeny, M Shah, GK Schwartz, A Tse, A Hamilton, ... Journal of clinical oncology 23 (9), 1803-1810, 2005 | 1434 | 2005 |
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study A Ohtsu, MA Shah, E Van Cutsem, SY Rha, A Sawaki, SR Park, HY Lim, ... Journal of clinical oncology 29 (30), 3968-3976, 2011 | 1409 | 2011 |
| Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study JM Sun, L Shen, MA Shah, P Enzinger, A Adenis, T Doi, T Kojima, ... The Lancet 398 (10302), 759-771, 2021 | 1174 | 2021 |
| Targeting the cell cycle: a new approach to cancer therapy GK Schwartz, MA Shah Journal of clinical oncology 23 (36), 9408-9421, 2005 | 1016 | 2005 |
| Oesophageal cancer EC Smyth, J Lagergren, RC Fitzgerald, F Lordick, MA Shah, P Lagergren, ... Nature reviews Disease primers 3 (1), 1-21, 2017 | 984 | 2017 |
| Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ... Journal of Clinical Oncology 38 (35), 4138-4148, 2020 | 884 | 2020 |
| Gastric cancer epidemiology and risk factors DE Guggenheim, MA Shah Journal of surgical oncology 107 (3), 230-236, 2013 | 719 | 2013 |
| Chemotherapy use, performance status, and quality of life at the end of life HG Prigerson, Y Bao, MA Shah, ME Paulk, TW LeBlanc, BJ Schneider, ... JAMA oncology 1 (6), 778-784, 2015 | 671 | 2015 |
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial E Van Cutsem, S de Haas, YK Kang, A Ohtsu, NC Tebbutt, J Ming Xu, ... Journal of clinical oncology 30 (17), 2119-2127, 2012 | 606 | 2012 |
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma MA Shah, RK Ramanathan, D Ilson, ... Journal of Clinical Oncology 24 (33), 5201-5206, 2006 | 585 | 2006 |
| Cell cycle-mediated drug resistance: an emerging concept in cancer therapy MA Shah, GK Schwartz Clinical cancer research 7 (8), 2168-2181, 2001 | 579 | 2001 |
| Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an … PC Thuss-Patience, MA Shah, A Ohtsu, E Van Cutsem, JA Ajani, H Castro, ... The lancet oncology 18 (5), 640-653, 2017 | 571 | 2017 |
| Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE … MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ... JAMA oncology 5 (4), 546-550, 2019 | 485 | 2019 |
| Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised … J Tabernero, PM Hoff, L Shen, A Ohtsu, MA Shah, K Cheng, C Song, ... The Lancet Oncology 19 (10), 1372-1384, 2018 | 484 | 2018 |
| Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline EP Balaban, PB Mangu, AA Khorana, MA Shah, S Mukherjee, CH Crane, ... Journal of Clinical Oncology 34 (22), 2654-2668, 2016 | 416 | 2016 |
| Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction … K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, ... The Lancet 401 (10389), 1655-1668, 2023 | 403 | 2023 |
| Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram VE Strong, KY Song, CH Park, LM Jacks, M Gonen, M Shah, DG Coit, ... Annals of surgery 251 (4), 640-646, 2010 | 403 | 2010 |
| Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline DPS Sohal, PB Mangu, AA Khorana, MA Shah, PA Philip, EM O’Reilly, ... Journal of Clinical Oncology 34 (23), 2784-2796, 2016 | 391 | 2016 |
Florian LordickUniversity Cancer Center LeipzigPatvirtintas el. paštas medizin.uni-leipzig.de
